Detalles de la búsqueda
1.
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Future Oncol;
17(7): 763-773, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33150799
2.
On the Interpretation of the Hazard Ratio and Communication of Survival Benefit.
Oncologist;
22(4): 484-486, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28314839
3.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet;
384(9944): 665-73, 2014 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24933332
4.
Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer.
J Med Econ;
26(1): 1479-1488, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38035666
5.
A portfolio-based approach to optimize proof-of-concept clinical trials.
J Biopharm Stat;
22(3): 596-607, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22416843
6.
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set.
ESMO Open;
3(3): e000347, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29713498
7.
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
Lung Cancer;
120: 62-69, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29748017
8.
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Clin Lung Cancer;
19(3): 270-279.e3, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373274
9.
International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
J Crit Care;
22(2): 142-52, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17548026
10.
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Lung Cancer;
112: 181-187, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29191593
11.
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.
J Gastric Cancer;
17(2): 132-144, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28680718
12.
International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
Curr Med Res Opin;
22(5): 1001-12, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16709322
13.
Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.
Curr Med Res Opin;
21(1): 135-40, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15881485
14.
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.
Crit Care;
9(6): R607-22, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16280057
15.
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
J Bone Miner Res;
19(8): 1270-5, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15231013
16.
Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.
J Clin Endocrinol Metab;
87(1): 122-8, 2002 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-11788634
17.
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial.
Am J Cardiol;
90(11): 1204-10, 2002 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12450599
18.
Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
Clin Ther;
25(3): 919-30, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12852708
19.
Comment on: Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
J Chemother;
29(1): 62-64, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27077927
20.
Comment on: Incidence and Risk of Hypertension with Ramucirumab in Cancer Patients: A Meta-Analysis of Published Studies.
Clin Drug Investig;
35(6): 405, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25910606